Balyasny Asset Management L.P. Takes $9.31 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Balyasny Asset Management L.P. acquired a new position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 548,761 shares of the biotechnology company's stock, valued at approximately $9,312,000. Balyasny Asset Management L.P. owned approximately 2.03% of Arcturus Therapeutics as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Ameriprise Financial Inc. boosted its position in shares of Arcturus Therapeutics by 5.0% in the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock valued at $316,000 after purchasing an additional 883 shares during the period. PDT Partners LLC boosted its holdings in shares of Arcturus Therapeutics by 20.2% in the fourth quarter. PDT Partners LLC now owns 90,298 shares of the biotechnology company's stock valued at $1,532,000 after acquiring an additional 15,154 shares during the period. Schonfeld Strategic Advisors LLC boosted its stake in Arcturus Therapeutics by 129.7% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock worth $14,409,000 after purchasing an additional 479,482 shares during the period. Northern Trust Corp boosted its stake in Arcturus Therapeutics by 5.6% during the 4th quarter. Northern Trust Corp now owns 256,332 shares of the biotechnology company's stock worth $4,350,000 after purchasing an additional 13,582 shares during the period. Finally, Boothbay Fund Management LLC acquired a new stake in shares of Arcturus Therapeutics during the fourth quarter worth about $1,000,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ARCT has been the subject of a number of recent research reports. BTIG Research set a $48.00 price objective on Arcturus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 10th. HC Wainwright reiterated a "buy" rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Canaccord Genuity Group cut their price objective on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a report on Friday, March 7th. Finally, Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, March 7th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $58.80.

Arcturus Therapeutics Price Performance

NASDAQ ARCT traded up $0.27 during trading hours on Tuesday, hitting $11.86. The company had a trading volume of 783,627 shares, compared to its average volume of 452,248. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $8.04 and a fifty-two week high of $45.00. The company has a market capitalization of $321.66 million, a price-to-earnings ratio of -5.34 and a beta of 2.36. The firm's 50 day moving average is $11.78 and its 200 day moving average is $15.38.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. The business had revenue of $29.38 million during the quarter, compared to analyst estimates of $25.64 million. On average, equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.